Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control (LIGHT)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT00700960

NN304-1859

Details and patient eligibility

About

This study is conducted in Europe. The aim of this observational study is to describe the conditions for the concomitant administration of a slow-acting insulin analogue with oral antidiabetics (OADs) in order to improve blood glucose control in type 2 diabetes.

Enrollment: 2,745 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes
• HbA1c level greater than 7% despite treatment with two (or three) oral antidiabetic drugs (OADs) at an optimal dose level
• Patient agreeing to take part in the study and capable of completing a self-questionnaire.

Exclusion criteria

• Hypersensitivity to insulin or to one of the excipients
• Treatment with insulin for at least 6 months
• Participant in a clinical trial for diabetes on entry into the observational study

Trial design

2,745 participants in 1 patient group

A

Treatment:

Drug: insulin detemir